JP2018526450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526450A5 JP2018526450A5 JP2018531280A JP2018531280A JP2018526450A5 JP 2018526450 A5 JP2018526450 A5 JP 2018526450A5 JP 2018531280 A JP2018531280 A JP 2018531280A JP 2018531280 A JP2018531280 A JP 2018531280A JP 2018526450 A5 JP2018526450 A5 JP 2018526450A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- promoter
- composition according
- early
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 36
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 241000700618 Vaccinia virus Species 0.000 claims 6
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 6
- 208000007089 vaccinia Diseases 0.000 claims 6
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 108010051152 Carboxylesterase Proteins 0.000 claims 4
- 102000013392 Carboxylesterase Human genes 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940126523 co-drug Drugs 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 3
- 101000898006 Homo sapiens Cocaine esterase Proteins 0.000 claims 3
- -1 IL-1α Proteins 0.000 claims 3
- 102000003996 Interferon-beta Human genes 0.000 claims 3
- 108090000467 Interferon-beta Proteins 0.000 claims 3
- 230000010102 embolization Effects 0.000 claims 3
- 229960002949 fluorouracil Drugs 0.000 claims 3
- 102000055467 human CES2 Human genes 0.000 claims 3
- 230000000174 oncolytic effect Effects 0.000 claims 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 101800003344 Vaccinia growth factor Proteins 0.000 claims 2
- 229960004117 capecitabine Drugs 0.000 claims 2
- 229960005395 cetuximab Drugs 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 2
- 235000008191 folinic acid Nutrition 0.000 claims 2
- 239000011672 folinic acid Substances 0.000 claims 2
- 229960001691 leucovorin Drugs 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 238000005457 optimization Methods 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 claims 1
- YSNABXSEHNLERR-ZIYNGMLESA-N 5'-Deoxy-5-fluorocytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)N=C(N)C(F)=C1 YSNABXSEHNLERR-ZIYNGMLESA-N 0.000 claims 1
- 101150049392 A34R gene Proteins 0.000 claims 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 1
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100023802 Somatostatin receptor type 2 Human genes 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108090000586 somatostatin receptor 2 Proteins 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562215651P | 2015-09-08 | 2015-09-08 | |
| US62/215,651 | 2015-09-08 | ||
| PCT/KR2016/009866 WO2017043815A1 (en) | 2015-09-08 | 2016-09-02 | Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526450A JP2018526450A (ja) | 2018-09-13 |
| JP2018526450A5 true JP2018526450A5 (enExample) | 2019-08-29 |
| JP6895968B2 JP6895968B2 (ja) | 2021-06-30 |
Family
ID=58240110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531280A Active JP6895968B2 (ja) | 2015-09-08 | 2016-09-02 | サイトカインおよびカルボキシルエステラーゼを発現する腫瘍溶解性改変ワクシニアウイルス、および、その使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10646524B2 (enExample) |
| EP (1) | EP3347460A4 (enExample) |
| JP (1) | JP6895968B2 (enExample) |
| KR (1) | KR102674362B1 (enExample) |
| CN (1) | CN108350434B (enExample) |
| AU (1) | AU2016320355B2 (enExample) |
| CA (1) | CA2996120C (enExample) |
| HK (1) | HK1255192A1 (enExample) |
| WO (1) | WO2017043815A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| CA2990133A1 (en) * | 2015-06-19 | 2017-03-09 | Sillajen, Inc. | Compositions and methods for viral embolization |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors |
| SG11201807051VA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| EP3610870A4 (en) * | 2017-03-31 | 2020-12-09 | Ogata, Hisanobu | METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| CN109554353B (zh) * | 2017-09-26 | 2021-08-06 | 杭州康万达医药科技有限公司 | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| WO2019148109A1 (en) * | 2018-01-26 | 2019-08-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Expression of metabolic modulators in tumor microenvironment to improve tumor therapy |
| CN118147029A (zh) | 2018-07-11 | 2024-06-07 | 阿克蒂姆治疗有限公司 | 工程化的免疫刺激性细菌菌株及其用途 |
| CN116162654A (zh) * | 2018-09-15 | 2023-05-26 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫疗法的重组痘病毒 |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| CA3176660A1 (en) | 2019-02-27 | 2020-09-03 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| KR20220082025A (ko) * | 2019-10-16 | 2022-06-16 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 변형된 세포외 외피보유 바이러스 |
| EP4058578A2 (en) | 2019-11-12 | 2022-09-21 | Actym Therapeutics, Inc. | Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products |
| WO2021116943A1 (en) * | 2019-12-12 | 2021-06-17 | Ignite Immunotherapy, Inc. | Variant oncolytic vaccinia virus and methods of use thereof |
| EP4196139A2 (en) | 2020-08-12 | 2023-06-21 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
| US20240102912A1 (en) * | 2020-11-09 | 2024-03-28 | Thrive Bioscience, Inc. | Plaque counting assay method |
| WO2022109133A1 (en) | 2020-11-19 | 2022-05-27 | Kalivir Immunotherapeutics, Inc. | Oncolytic immunotherapy by tumor micro-environment remodeling |
| WO2022232375A1 (en) | 2021-04-30 | 2022-11-03 | Kalivir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| JP2024542173A (ja) | 2021-11-09 | 2024-11-13 | アクティム・セラピューティクス・インコーポレイテッド | マクロファージを処置に適している表現型に変換するための免疫刺激細菌および処置のための対象の同定のためのコンパニオン診断法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080046750A (ko) * | 2000-03-24 | 2008-05-27 | 바이오스피어 메디칼 인코포레이티드 | 능동 색전화용 미소구 |
| AU2003258168B2 (en) * | 2002-08-12 | 2009-10-29 | Sillajen Biotherapeutics, Inc. | Methods and compositions concerning poxviruses and cancer |
| EP1933857A2 (en) * | 2005-09-07 | 2008-06-25 | Jennerex Biotherapeutics ULC | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| CN103429258B (zh) * | 2011-01-04 | 2016-03-09 | 新罗杰公司 | 通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性 |
| SMT202400047T1 (it) * | 2013-08-22 | 2024-03-13 | Univ Pittsburgh Commonwealth Sys Higher Education | Terapie immuno-oncolitiche |
-
2016
- 2016-09-02 WO PCT/KR2016/009866 patent/WO2017043815A1/en not_active Ceased
- 2016-09-02 CA CA2996120A patent/CA2996120C/en active Active
- 2016-09-02 HK HK18114315.9A patent/HK1255192A1/zh unknown
- 2016-09-02 JP JP2018531280A patent/JP6895968B2/ja active Active
- 2016-09-02 EP EP16844635.9A patent/EP3347460A4/en not_active Withdrawn
- 2016-09-02 KR KR1020187009770A patent/KR102674362B1/ko active Active
- 2016-09-02 US US15/758,689 patent/US10646524B2/en active Active
- 2016-09-02 CN CN201680064990.2A patent/CN108350434B/zh active Active
- 2016-09-02 AU AU2016320355A patent/AU2016320355B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526450A5 (enExample) | ||
| Park et al. | Phase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer | |
| Kowalsky et al. | Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade | |
| Vilgelm et al. | Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy | |
| Leoni et al. | A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors | |
| JP6949131B2 (ja) | 治療用ｒｎａ | |
| Takeda et al. | A TLR3-specific adjuvant relieves innate resistance to PD-L1 blockade without cytokine toxicity in tumor vaccine immunotherapy | |
| CN110913871B (zh) | 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法 | |
| Bao et al. | The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis | |
| Fridlender et al. | Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms | |
| Vacchelli et al. | Trial Watch—Immunostimulation with cytokines in cancer therapy | |
| Hashimoto et al. | Type I IFN gene delivery suppresses regulatory T cells within tumors | |
| Li et al. | The interplay between inflammation and stromal components in pancreatic cancer | |
| Liu et al. | Drug resistance and tumor immune microenvironment: An overview of current understandings | |
| CN108635380A (zh) | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 | |
| Karagiannidis et al. | G-CSF and G-CSFR modulate CD4 and CD8 T cell responses to promote colon tumor growth and are potential therapeutic targets | |
| WO2018228538A1 (zh) | 重组单纯疱疹病毒及其制备方法和应用 | |
| JP2022543555A (ja) | ｍｉＲＮＡ－１９３ａに関する新たな処置 | |
| JP2022524391A (ja) | 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 | |
| Malhotra et al. | Oncolytic viruses and cancer immunotherapy | |
| Di Carlo et al. | Depletion of slow-cycling PDGFRα+ ADAM12+ mesenchymal cells promotes antitumor immunity by restricting macrophage efferocytosis | |
| JP2019532047A (ja) | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ | |
| Ma et al. | High-dose VitC plus oncolytic adenoviruses enhance immunogenic tumor cell death and reprogram tumor immune microenvironment | |
| Perales-Puchalt et al. | IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment | |
| Du et al. | Therapeutic potential of targeting stromal crosstalk-mediated immune suppression in pancreatic cancer |